Search by PDG name  



      Official symbol:  ERBB2
      Full name:  erb-b2 receptor tyrosine kinase 2
      Location:  17q12
      Also known as:  HER2, NEU, CD340, NGL, HER-2
      Entrez ID:  2064
      Ensembl ID:  ENSG00000141736
      Summary:  This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]


  Overall distribution
  Tissue specific distribution
Cancer specific in breast cancer subtype (Her2)

  Overall distribution
  Tissue specific distribution
Gscore (Amp):  5.86  (Driver)
Gscore (Del):  0.00  
Recurrently amplified in 11 cancer type(s)

  Overall distribution
  Tissue specific distribution
Mscore:  0.85  (Driver)
Recurrently mutated in 6 cancer type(s)

  Tissue specific
Total fusion occurrence:  21  (Driver)
Fusions detected in 9 cancer type(s)

  Tissue specific

      Functional class:  Kinase (protein kinase)
      JensenLab PubMed score:  20244.63  (Percentile rank: 99.89%)
      PubTator score:  16162.96  (Percentile rank: 99.92%)
      Target development/druggability level:  TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action.
      Tractability (small molecule):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
      Tractability (antibody):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets


Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.